1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind sets eyes on 5x growth.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 September 2024, including: Johnson & Johnson interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind Pharma Ltd. sets eyes on 5x growth.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "J&J Interested In ‘Differentiated’ Obesity Assets" - Scrip, 4 September, 2024.)

(Also see "ESC: Kerendia Hits In Heart Failure, But Usage Unclear" - Scrip, 1 September, 2024.)

(Also see "Strong HERCULES Data Keep Sanofi’s MS Plans Alive" - Scrip, 2 September, 2024.)

(Also see "WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention" - Scrip, 2 September, 2024.)

(Also see "Fast And Furious – Leqvio Licensed, Bharat Serums In Bag, Mankind Sets Eyes On 5X Growth" - Scrip, 3 September, 2024.)

Citeline · Scrip’s Five Must-Know Things - 9 September 2024

Open Media

More from Alimentary/Metabolic

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Metsera’s Phase IIb GLP-1 Data Show Competitive Efficacy, Tolerability

 
• By Joseph Haas

A week after Pfizer bid $4.9bn to acquire Metsera, the biotech reported mid-stage data showing 28-week efficacy comparable to tirzepatide and a “placebo-like” rate of diarrhea.

Acadia Gives Up In PWS After Another ACP-101 Phase III Miss

 
• By Joseph Haas

Acquired after an FDA advisory panel rejection in 2021, the oxytocin analog nasal spray was being positioned as a second drug to market for the rare disease Prader-Willi syndrome.

Roche Highlights Pipeline Transformed By Deals And ‘Raising The Bar’

 
• By Andrew McConaghie

The Swiss company believes new rigor in its internal decision-making and focus on best-in-class efficacy will deliver strong growth to 2030 and beyond.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.